GC Green Cross Confirms Antibody Formation in Phase 1 Clinical Trial of Shingles Vaccine

[Asia Economy Reporter Hyun-ui Cho] GC Green Cross announced on the 16th that its US subsidiary Curevo confirmed antibody formation in the Phase 1 clinical trial of the next-generation shingles vaccine ‘CRV-101’.

CRV-101 is a next-generation shingles vaccine developed by Curevo in the US using a recombinant gene technology method, utilizing a novel immune adjuvant composed solely of highly pure synthetic substances.

This Phase 1 clinical trial involved 89 healthy adults who were administered two doses of the vaccine at 56-day intervals with varying doses of antigen and immune adjuvant, after which antibody formation in the body was measured. The study results showed that antibodies were formed in all subjects one month after vaccination, and these antibodies were confirmed to be maintained for one year.

No severe adverse events of grade 3 or higher were observed. Grade 2 adverse events, including pain at the injection site, occurred in less than 6.5% of the total test group.

The company plans to present these research results at the World Vaccine Conference held online on the 30th. The final results of Phase 1 clinical trials, which also confirmed the cellular immunogenicity of this vaccine, will be disclosed early next year.

George Simon, CEO of Curevo, said, "Following last year’s safety confirmation, we have confirmed results exceeding expectations in antibody formation," and added, "We will accelerate the research pace to enter Phase 2 clinical trials as soon as possible."